Presentation

Integrum AB is based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy an improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.

Recent highlights
During the quarter of February 1st – April 30th, net sales amounted to 18.3M SEK (+47.4% compared to the same period last year).
In December, Integrum announced that it has been selected as a strategic partner for the US Dept of Veterans Affairs to establish the OPRATM Implant System as a standard treatment for veterans. During H1 2022, integrum announced that several hospitals worldwide had completed treatments with its OPRATM Implant System, including the Erie County Medical Center in New York, BG Klinikum and Hannover Medical School in Germany, and Oslo University Hospital. In June, the company carried out a directed issue raising approximately 121M SEK.

Outlook
The company’s growth strategy is mainly driven by its investments in the US, all of which aim to establish the OPRATM Implant System as a standard of care in the US.